Adenosine Suppresses Cholangiocarcinoma Cell Growth and Invasion in Equilibrative Nucleoside Transporters-Dependent

Kornkamon Lertsuwan1,2, Supathra Phoaubon1, Nathapol Tasnawijitwong3

  • 1Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.

Insights

Adenosine inhibits cholangiocarcinoma (CCA) growth by entering cells through equilibrative nucleoside transporters (ENTs), not by activating receptors. This pathway involves adenosine kinase and impacts AMP levels, suppressing cancer progression.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cholangiocarcinoma (CCA) is an aggressive cancer with rising global incidence.
  • Previous research indicated CCA's sensitivity to adenosine, suggesting therapeutic potential.

Purpose of the Study:

  • To elucidate the molecular mechanisms by which adenosine inhibits cholangiocarcinoma (CCA) cell growth.
  • To investigate the role of adenosine transporters and receptors in adenosine-mediated CCA inhibition.

Main Methods:

  • Investigated adenosine uptake via equilibrative nucleoside transporters (ENTs) and adenosine receptors.
  • Utilized NBTI (ENT inhibitor) and receptor antagonists (caffeine, CGS-15943).
  • Assessed intracellular adenosine and AMP levels, and 5′ AMP-activated protein kinase (AMPK) activation.

Main Results:

  • Adenosine inhibited CCA cells through ENT-mediated uptake, not receptor activation.
  • Inhibition of ENTs with NBTI abolished adenosine's effect; receptor antagonists had no impact.
  • Intracellular adenosine and AMP levels increased, leading to AMPK activation.
  • A metabolically stable adenosine analog, 2Cl-adenosine, showed enhanced inhibition.

Conclusions:

  • Adenosine suppresses CCA cell growth and invasion via a novel, receptor-independent mechanism.
  • The pathway involves adenosine transport via ENTs, intracellular conversion to AMP, and subsequent AMPK activation.
  • Targeting adenosine transport presents a potential therapeutic strategy for cholangiocarcinoma.